Veru Inc. (NASDAQ:VERU) Stock Ratings Reduced By TheStreet
According to data compiled by TheStreetRatingsTable, on Thursday, shares of Veru (NASDAQ:VERU) were lowered by TheStreet from a c rating to a d rating.
Other research analysts have published similar studies in recent weeks. In a study published on Thursday, Cantor Fitzgerald increased their price target for Veru from $24.00 to $30.00. On Wednesday, May 18th, Brookline Capital Acquisition upgraded Veru from a buy recommendation to a $31.00 price target in a research report.
On Friday, May 13th, Jefferies Financial Group published a report that increased their price target on Veru from $33.00 to $55.00. At the end of the day on May 18th, research firm Brookline Capital Management upgraded Veru from a buy recommendation to a $31.00 price target in a report.
Five market analysts have given the stock buying recommendation. MarketBeat shows that the current consensus price objective for Veru is $34.50, with an average rating of Buy.
Veru Stock Price Rises 19.2%
Thursday’s opening price for VERU shares was $19.08. A year of Veru’s price data shows a range from $4.34 to $19.25. Investors are bidding up the stock’s $1.53 billion market value thanks to its low P/E of -32.34 and low beta of 0.40. The 50-day MA for the stock is at $13.48, and the 200-day MA is at $10.11.
The last time we heard from Veru (NASDAQ:VERU) was on Thursday, May 12th, when the company announced its most recent quarterly results.
A consensus estimate of ($0.16) was expected, so the company’s actual EPS of ($0.18) was ($0.02). Return on equity for Veru was negative at 32.35%, and the net margin was negative at 89.77%.
The company earned $13.03 million in the quarter, below the $15.18 million predicted by market analysts. The company lost money per share in the same quarter a year ago, bringing in only $0.04.
Industry experts agree that Veru’s current fiscal year will end with the company reporting negative earnings per share of -0.58.
Veru Exchange Traded in Institutions
Many large investors, including hedge funds and pension funds, have recently traded in and out of the company’s stock. In the second quarter, UBS Group AG increased its holdings in Veru by 2.3%.
After purchasing an additional 890 shares during the quarter, UBS Group AG now holds 39,216 shares of the company’s stock, worth $443,000. In the second quarter, Ensign Peak Advisors Inc increased its holdings in Veru by 18.6 percent.
After purchasing an additional 1,600 shares during the reporting period, Ensign Peak Advisors Inc now holds 10,220 shares of the company’s stock, with a market value of $115,000.
The Texas Teacher Retirement System increased its holdings in Veru by 22.4% during the fourth quarter. After acquiring an additional 2,258 shares during the time, the Teacher Retirement System of Texas now holds 12,360 shares of the company’s stock, with a total value of $73,000.
XTX Topco Ltd increased its holdings in Veru by 18.7 percent in the first three months of the year.
With the 2,270 shares it purchased during the reporting period, XTX Topco Ltd’s total holdings in the company’s stock increased to 14,426 shares, with a market value of $70,000.
At the end of the second quarter, Russell Investments Group Ltd. invested an additional $25,000 in shares of Veru. Institutional investors and hedge funds own 29.11 percent of the company’s shares.
Executive Summary: The Veru Inc.
To what extent is this true?
Founded in 2012, Veru Inc is an oncology biopharmaceutical firm researching and developing cancer treatments. The FC2 female condom/internal condom is offered commercially to ministries of health, government health agencies, the United Nations, and other organizations to prevent unwanted pregnancies and the spread of STIs.